Abstract:Purpose: Accumulating evidence that apolipopro-tein B (apoB) plays a critical role in predicting coronary heart disease (CHD) and future outcomes. The 2019 European Society of Cardiology/European Atherosclerosis Society guidelines suggest that apoB can be an alternative to non-HDL-C or LDL-C in patients with high triglyceride levels, diabetes, obesity, metabolic syndrome, or very low LDL-C levels. This study explores whether apoB can also serve as predictive value for long-term major adverse cardiovascular events (MACEs) in normal people and specific coronary atherosclerosis patients.Methods: A total of 826 patients were followed up over 10 years, and the risk factors for MACEs were retrospectively analyzed in patients with CHD and particular subpopulations. All statistical analyses were performed in R software. Cox regressions were performed to assess independent risk factors of long-term MACEs in the atherosclerosis group and CHD subgroups. Kaplan-Meier survival curves were used to evaluate the survival rate for patients in different apoB quartiles, and receiver-operating characteristic curves were used to compare apoB and other lipids in predicting the presence of long-term MACE.Findings: apoB could be a "risk-enhancing factor" in patients with coronary atherosclerosis disease, whereas in the Normal population, LDL-C still acted as a major risk factor for predicting MACEs. apoB was a good risk predictor for long-term cardiovascular events in coronary atherosclerosis (AS) patients, including the AS group and CHD subpopulations (including CHD + triglyceride >2.3 mmol/L, CHD + diabetes mellitus, CHD + body mass index >25 kg/m2, or CHD + metabolic syndrome). In patients with CHD whose condition was complicated with diabetes, obesity, and metabolic syndrome, apoB performed better than other lipids in predicting the presence of myocardial infarction, hospitalization due to angina, and cardiac death. Despite achieving optimal LDL-C or non-HDL-C levels, patients with CHD are still at risk of worse survival if they are unable to reach a low apoB level (lower cut points such as 65 mg/dL).Implications: More attention should be paid to special populations with residual elevations of athero-genic particle numbers, and greater focus should be placed on lowering baseline apoB to achieve long-term benefits. However, given that this was an observational study, the association of baseline apoB level and long-term MACEs only was evaluated; it is unclear whether the emergence of MACEs would be influenced by the dynamic changes of apoB. Because this was a retrospective and observational analysis, bias in data analysis was unavoidable; thus, the results cannot be used to generalize implications to broader patient populations, and more large-scale clinical trials are required to verify these findings.(Clin Ther. 2022;44:1071-1092) (c) 2022 Elsevier HS Journals, Inc. (Clin Ther. 2022;44:1071-1092.)(c) 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC -ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study

Association of apolipoprotein B with all-cause and cardiovascular mortality among adults: Results from the National Health and Nutrition Examination Surveys

Abstract P268: Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients

Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients.

Serum apolipoproteins and mortality risk: evidence from observational and Mendelian randomization analyses

The association of apolipoprotein B with chronic kidney disease in the Chinese population

Serum Apolipoprotein B is Associated with Increased Risk of Metabolic Syndrome among Middle‐aged and Elderly Chinese: A Cross‐sectional and Prospective Cohort Study

Serum Apob Levels Independently Predict the Development of Non-Alcoholic Fatty Liver Disease: A 7-Year Prospective Study

HDL-C, Longitudinal Change and Risk of Mortality in a Chinese Cohort Study.

Longitudinal Change in Blood Pressure is Associated with Cardiovascular Disease Mortality in a Chinese Cohort.

Paradoxical Association Between Baseline Apolipoprotein B and Prognosis in Coronary Artery Disease: A 36,460 Chinese Cohort Study

Correlation Between Small and Dense Low‐density Lipoprotein Cholesterol and Cardiovascular Events in Beijing Community Population

Differences in HDL-related mortality risk between individuals with and without hypertension: a prospective cohort study in UK Biobank

[Association of High-Density Lipoprotein Cholesterol with Risk of Cardiovascular Disease Mortality].

The Correlation between Serum Phospholipid Fatty Acids and Blood Lipids in Hypertension

Apolipoprotein B Displays Superior Predictive Value Than Other Lipids for Long-Term Prognosis in Coronary Atherosclerosis Patients and Particular Subpopulations: A Retrospective Study.

An Association Study of Lipoprotein and Apolipoprotein Levels in the Coronary Heart Disease

Cumulative exposure to high remnant-cholesterol concentrations increases the risk of cardiovascular disease in patients with hypertension: a prospective cohort study

Both Serum Apolipoprotein B And The Apolipoprotein B/Apolipoprotein A-I Ratio Are Associated With Carotid Intima-Media Thickness

Blood Lipids, Lipoproteins, and Apolipoproteins With Risk of Coronary Heart Disease: A Prospective Study Among Racially Diverse Populations

Association of serum apolipoprotein B with cerebrospinal fluid Alzheimer’s disease biomarkers in patients with subjective cognitive decline